For this purpose, a clinical drug L-asparaginase (L-ASP), which catalyzes the hydrolysis of asparagine to aspartate and used in the treatment of acute lymphoblastic leukemia (ALL) in children [20, 21], was used in this study to enzymatically deplete glutamine by its glutaminase activity [22, 23]. This evidence concerns the gene GLS and acute lymphoblastic leukemia.